A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

CC-96673

IV Infusion

Trial Locations (13)

28027

Local Institution - 401, Madrid

29010

Local Institution - 403, Málaga

34295

Local Institution - 302, Montpellier

37007

Local Institution - 402, Salamanca

49933

Local Institution - UNK-5, Angers

55455

Local Institution - 104, Minneapolis

59037

Local Institution - 303, Lille

69310

Hopital Lyon Sud, Pierre-Bénite

77030

Local Institution - 101, Houston

98124

Local Institution - 102, Seattle

68198-6840

Local Institution - 103, Omaha

M5G 2M9

Local Institution - 201, Toronto

H3T 1E2

Local Institution - 202, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT04860466 - A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter